Literature DB >> 3665996

Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. EORTC Pharmacokinetics and Metabolism Group.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3665996     DOI： 10.1016/0277-5379(87)90365-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  16 in total

Review 1.  Choice of starting dose and escalation for phase I studies of antitumor agents.

Authors:  J S Penta; G L Rosner; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

3.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?

Authors:  L S Freedman; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  Concentration-controlled trials. What does the future hold?

Authors:  A Johnston; D W Holt
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 6.  Limited-sampling models for anticancer agents.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.

Authors:  N S Stuart; S M Crawford; G R Blackledge; E S Newlands; J Slack; R Hoffman; M F Stevens
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

Authors:  V Reichelová; G Juliusson; T Spasokoukotskaja; S Eriksson; J Liliemark
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTG.

Authors:  J Cassidy; M A Graham; W Ten Bokkel Huinink; C McDaniel; A Setanoians; E M Rankin; D J Kerr; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.